Skip Navigation


European Journal of Echocardiography Advance Access originally published online on March 27, 2009
European Journal of Echocardiography 2009 10(4):465-466; doi:10.1093/ejechocard/jep032
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/4/465    most recent
jep032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Badano, L. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badano, L. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Contrast enhanced real-time three-dimensional echocardiography for quantification of myocardial perfusion: a step forward

Luigi P. Badano

Department of Cardiopulmonary Sciences, University Hospital ‘S Maria della Misericordia’, P.le S Maria della Misericordia 15, 33100 Udine, Italy

Corresponding author. Tel: +39 0432 552444; fax: +39 0432 482353. E-mail address: badano.luigi@aoud.sanita.fvg.it

The first 10% of the full text of this article appears below.

Many studies have shown the feasibility of contrast two-dimensional echocardiography (2DE) for myocardial perfusion imaging.1 The technique offers several important advantages over competing techniques including its wide availability, portability, low cost, no radiation concern, and the simultaneous visualization of wall motion and perfusion. However, contrast echocardiography has not become a routine procedure both for the diagnosis and assessment of ischaemic heart disease in daily practice. There are several reasons for this: no echo contrast agent has been specially approved for myocardial perfusion imaging, there are concerns about safety and reimbursement issues. In addition, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?